Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

STEMTARGET

Financiado

Cerrado

Targeting Leukemia Stem Cells

"Targeting Leukemia Stem Cells The major goals of STEMTARGET is to identify novel targets on leukemic stem cells (LSCs), generate novel insights into LSC biology, and to initiate the development of LSC-directed therapeutic antibo... ver más

28/02/2018

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

MAX IV Laboratory, Lund University No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

100.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

T2Lead Define a lead candidate for clinical development of a novel... 150K€ Cerrado

PID2019-105404RB-I00 GENERATION DE NUEVAS HERRAMIENTAS IMMUNOTERAPEUTICAS PARA EL... 127K€ Cerrado

Hemstem Targeting leukaemia by modulating hematopoietic stem cell co... 2M€ Cerrado

IMMUNOTHERAPY IN CML Combined application of targeted therapy and immunotherapy i... 100K€ Cerrado

CARxALL Next generation, off-the-shelf, non fratricide-directed, CAR... 2M€ Cerrado

CPP2021-008508 Desarrollo de una nueva terapia CAR-T dirigida a CD1a para e... 1K€ Cerrado

Líder del proyecto

MAX IV Laboratory, Lund University No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Targeting Leukemia Stem Cells The major goals of STEMTARGET is to identify novel targets on leukemic stem cells (LSCs), generate novel insights into LSC biology, and to initiate the development of LSC-directed therapeutic antibodies. The research will focus on three specific aims: (I) To characterize novel cell surface targets on LSCs, identified by in vivo RNA interference screens. (II) To utilize an in-house developed cytokine screen for identification of cell surface targets selectively important for LSCs. (III) To measure receptor expression in patient samples and demonstrate proof of concept for therapeutic effect with antibody-treatment of leukemic mice. Background: In adults, AML has a poor prognosis, and novel therapies are needed. In order to be maximally effective, an important goal for the development of novel treatments is to target all leukemia cells with the ability to self renew and maintain the disease indefinitely, a population termed LSCs. During Dr Järås postdoctoral training at Harvard Medical School, Boston, he and coworkers developed a potent in vivo shRNA screen and used it to identify therapeutic targets in LSCs, towards both small molecules and blocking antibodies could be directed. In addition, Dr Järås has developed a cytokine screen for identification of cell surface targets selectively important for LSCs. In STEMTARGET, Dr Järås and coworkers will perform further shRNA screens and cytokine screens for the identification and characterization of candidate therapeutic targets on LSCs. Monoclonal antibodies targeting identified cell surface targets will be generated and proof of concept experiments for therapeutic targeting will be performed by treating mice with established leukemia. Successful completion of this research program will identify novel targets on LSC, and provide initial validation of therapeutic potential."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores